Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 17/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997819 | 1.00 | METTL3 (0.42) | METTL3KLKB1KDM4ETP53MEN1 | |
| SCHEMBL30997805 | 0.84 | METTL3 (0.42) | METTL3KLKB1KDM4ETP53 | |
| SCHEMBL24739081 | 0.84 | METTL3 (0.42) | METTL3KLKB1KDM4ETP53 | |
| SCHEMBL27033897 | 0.84 | METTL3 (0.45) | METTL3KLKB1 | |
| SCHEMBL29957586 | 0.84 | METTL3 (0.45) | METTL3KLKB1 | |
| SCHEMBL30997864 | 0.83 | KLKB1 (0.44) | METTL3KLKB1KDM4ETP53 | |
| SCHEMBL24739073 | 0.83 | KLKB1 (0.44) | METTL3KLKB1KDM4ETP53 | |
| SCHEMBL29958341 | 0.82 | METTL3 (0.46) | METTL3KLKB1 | |
| SCHEMBL29957790 | 0.82 | METTL3 (0.42) | METTL3KLKB1KDM4ETP53 | |
| SCHEMBL27033530 | 0.82 | METTL3 (0.46) | METTL3KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | METTL3 4596/4885KLKB1 1/4885KDM4E 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.